【摘要】 目的 :为了探讨沙利度胺对正常人和多发性骨髓瘤 (MM)患者骨髓造血祖细胞功能的影响及其作用机制。方法 :体外用甲基纤维素半固体方法培养经不同浓度沙利度胺处理过的正常人和MM患者骨髓GM CFU、E CFU、MK CFU的形成 ,用ELISA法检测祖细胞悬液IFN γ、TNF α水平。结果 :当沙利度胺浓度≥ 2 0 0 μg ml或≥ 1 0 0 μg ml时分别对正常人或MM患者GM CFU的形成有抑制作用 ;当沙利度胺浓度≥ 30 0 μg ml或≥ 1 50 μg ml时分别对正常人或MM患者MK CFU的形成有抑制作用 ;但 1 0～ 40 0 μg ml浓度的沙利度胺对正常人和MM患者的E CFU的形成均无影响 ;沙利度胺≥ 1 0 0 μg ml或≥ 2 0 0 μg ml时分别使MM患者和正常人骨髓造血祖细胞分泌的INF γ水平增高 ,沙利度胺浓度≥ 30 0 μg ml时MM患者TNF α水平减少。 结论 :不同浓度的沙利度胺对正常人和MM患者骨髓造血祖细胞的造血功能产生不同的影响 ,其作用机制可能与沙利度胺增加正常人或MM患者的造血祖细胞IFN γ分泌水平有关更多还原

【Abstract】 Objective:To study the influence and mechanism of thalidomide on bone marrow hematopoietic progenitor cells in multiple myeloma patients and in normal controls.Methods:Bone marrow GM CFU, E CFU and MK CFU from multiple myeloma patients and from normal controls were cultured in methylcellulose semisolid medium in vitro after being treated by different concentration of thalidomide. IFN γ and TNF α concentration in cell suspension of bone marrow hematopoietic progenitor cells from multiple myeloma patients and from normal controls were measured by ELISA.Results:Thalidomide inhibited GM CFU in multiple myeloma patients and in normal controls at concentration higher than 200 and 100 μg/ml, respectively, and inhibited MK CFU in multiple myeloma patients and in normal controls at concentration higher than 300 μg/ml and 150 μg/ml, respectively. However, there was no significantly influence of thalidomide on E CFU in multiple myeloma patients and in normal controls at concentration between 10 and 400 μg/ml. Thalidomide increased IFN γ concentration in cell suspension of bone marrow hematopoietic progenitor cells from multiple myeloma patients and from normal controls at concentration greater than 100 and 200 μg/ml, respectively. The level of thalidomide of higher than 300 μg/ml reduced TNF α concentration in cell suspension of bone marrow hematopoietic progenitor cells from multiple myeloma patients.Conclusion:Different concentrations of thalidomide have different influences on the hematopoietic function of bone marrow hematopoietic progenitor cells in multiple myeloma patients and in normal controls, probably mediated through increased IFN γ by thalidomide.更多还原